Véronique L. Roger, MD, MPH, FAHA; Alan S. Go, MD; Donald M. Lloyd-Jones, MD, ScM, FAHA; Emelia J. Benjamin, MD, ScM, FAHA; Jarett D. Berry, MD; William B. Borden, MD; Dawn M. Bravata, MD; Shifan Dai, MD, PhD*; Earl S. Ford, MD, MPH, FAHA*; Caroline S. Fox, MD, MPH; Heather J. Fullerton, MD; Cathleen Gillespie, MS*; Susan M. Hailpern, DPH, MS; John A. Heit, MD, FAHA; Virginia J. Howard, PhD, FA...

Patients —Texas, Arkansas, and Florida, 2008–2013 Anne Purfield, PhD; Snigdha Vallabhaneni, MD, MPH; Kaitlin Benedict, MPH; Shawn Lockhart, PhD; Cau Pham, PhD; Ulzii Luvsansharav, MD, PhD; Wendy Chung, MD, MSPH; Emily Hall, MPH; Jordan Peart; Neil Pascoe RN, BSN; Gary Heseltine, MD, MPH; Charlotte Wheeler, RN; Karen Brust, MD; Sharon Holmes, MPH; Prinu Gabriel, MS; Justin Groves, MPH; Craig Gil...

OBJECTIVES To evaluate the prevalence of methylphenidate (MPH) use among 5th and 6th year medical students, to discriminate MPH use with and without medical indication, and to correlate MPH use with alcohol intake. METHODS This is a cross-sectional study in which medical students were invited to answer a questionnaire to evaluate academic and socioeconomic status, MPH use patterns, and attitu...

BACKGROUND Attention-deficit/hyperactivity disorder (ADHD) symptoms are most commonly treated with stimulant medication such as methylphenidate (MPH); however, approximately 25% of patients show little or no symptomatic response. We examined the extent to which initial changes in brain functional connectivity (FC) associated with the first MPH dose in boys newly diagnosed with ADHD predict MPH-...

Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent neuropsychiatry disorders in children and adolescents, and methylphenidate (MPH) is a first-line stimulant drug available worldwide for its treatment. Despite the proven therapeutic efficacy, concerns have been raised regarding the possible consequences of chronic MPH exposure during childhood and adolescence. Disturba...

BACKGROUND Methylphenidate (MPH) is the most common drug treatment of attention deficit / hyperactivity disorder (ADHD) in children. Treatment with MPH is contraindicated in the presence of certain psychiatric, cerebro- and cardiovascular conditions. We assessed MPH treatment prevalence and incidence and the frequency of comorbid conditions related to these contraindications in new MPH users co...

Valentin Fuster, MD, PhD; Deepak L. Bhatt, MD, MPH; Robert M. Califf, MD; Alan D. Michelson, MD; Marc S. Sabatine, MD, MPH; Dominick J. Angiolillo, MD, PhD; Eric R. Bates, MD; David J. Cohen, MD, MSc; Barry S. Coller, MD; Bruce Furie, MD; Jean-Sebastien Hulot, MD, PhD; Kenneth G. Mann, PhD; Jessica L. Mega, MD, MPH; Kiran Musunuru, MD, PhD, MPH; Christopher J. O’Donnell, MD, MPH; Matthew J. Pri...

Exposure to Tap Water from a Treated Public Drinking Water System Jennifer Cope, MD, MPH; Raoult Ratard, MD, MPH; Jonathan S. Yoder, MSW, MPH; Theresa Sokol, MPH; Jake Causey; Vincent Hill PhD; Bonnie Mull, MPH; Kimberly Mukerjee, MD, MPH; Harlan Stern, MD; Meggie Doucet, MD; Gayatri Mirani, MD; Russell Van Dyke, MD; Michael Beach, PhD; Waterborne Disease Prevention Branch, Centers for Disease ...

M a i n r e s u l t s Results are in the Table. CLON (used alone or with MPH) compared with no CLON, MPH (used alone or with CLON) compared with no MPH, and combined CLON and MPH compared with placebo showed beneficial effects for ADHD symptoms as measured by the ASQ-Teacher. The greatest benefit was seen with combined CLON and MPH, which was most effective for lessening tic severity and improv...